Emerging Environmental Threats to Ovarian Reserve: The Association Between Novel PFAS Exposure and Premature Ovarian Insufficiency

Highlights

• Novel PFAS replacements, including HFPO-DA (GenX), PFBA, PFPeA, and PFPeS, are significantly associated with an increased risk of premature ovarian insufficiency (POI).
• Exposure to chemical mixtures of novel PFAS demonstrates a synergistic effect, worsening the risk of ovarian dysfunction compared to single-compound exposure.
• High plasma concentrations of these substances correlate strongly with objective markers of diminished ovarian reserve, specifically reduced anti-Müllerian hormone (AMH) and antral follicle count (AFC).
• The shift from legacy long-chain PFAS to shorter-chain or ether-structured ‘novel’ PFAS does not mitigate reproductive toxicity, necessitating urgent clinical and environmental policy re-evaluation.

Background

Premature ovarian insufficiency (POI) is a clinical syndrome defined by the loss of ovarian activity before the age of 40. It is characterized by menstrual disturbance (amenorrhea or oligomenorrhea), elevated gonadotropins (FSH > 25 IU/L), and low estradiol levels. Affecting approximately 1% of the global female population, POI has profound implications for fertility, cardiovascular health, and bone density. While genetic, autoimmune, and iatrogenic factors are known contributors, the etiology remains idiopathic in over 50% of cases, pointing toward the significant role of environmental endocrine-disrupting chemicals (EDCs).

Per- and poly-fluoroalkyl substances (PFAS) are a diverse group of synthetic chemicals used extensively in industrial and consumer products for their water- and oil-repellent properties. Historically, ‘legacy’ PFAS such as perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) have been linked to reproductive issues. However, due to regulatory restrictions, industry has shifted toward ‘novel’ PFAS alternatives, characterized by shorter carbon chains or the inclusion of ether linkages (e.g., HFPO-DA). Recent evidence suggests these novel substances are not only as persistent in the environment as their predecessors but may also pose equal or greater risks to human reproductive health.

Key Content

The Legacy of PFAS and Ovarian Health

The relationship between PFAS and ovarian aging was first established through studies on legacy compounds. Research published in the Journal of Clinical Endocrinology & Metabolism (2018) highlighted that Chinese women with overt POI had significantly higher plasma levels of PFOA, PFOS, and perfluorohexanesulfonate (PFHxS). Specifically, women in the highest tertile of PFOA exposure faced a nearly four-fold increase in POI risk (OR 3.80; 95% CI 1.92-7.49). These legacy substances were shown to correlate with elevated FSH and decreased estradiol, suggesting a direct impact on the hypothalamic-pituitary-ovarian (HPO) axis and possibly interference with thyroid function and prolactin regulation.

Clinical Evidence for Novel PFAS Exposure

As the chemical landscape has evolved, recent studies have begun to map the impact of novel PFAS. A pivotal 2025 case-control study (Qiao et al.) involving 371 women investigated thirteen types of novel PFAS. The findings revealed that concentrations of hexafluoropropylene oxide dimer acid (HFPO-DA), perfluorobutanoic acid (PFBA), perfluoropentanoic acid (PFPeA), and perfluoropentanesulfonic acid (PFPeS) were markedly higher in women diagnosed with POI compared to healthy controls.

Adjusted logistic regression models in this cohort demonstrated significant positive associations:

• HFPO-DA: ORadj 2.89 (95% CI: 1.84-4.53)
• PFBA: ORadj 1.54 (95% CI: 1.17-2.02)
• PFPeA: ORadj 3.12 (95% CI: 2.20-4.43)
• PFPeS: ORadj 2.07 (95% CI: 1.31-3.27)

These values represent the increased risk per 2.7-fold increase in plasma concentrations, indicating a robust dose-response relationship between novel PFAS exposure and the incidence of POI.

Impact on Ovarian Reserve Markers

Beyond the clinical diagnosis of POI, novel PFAS show a clear negative correlation with quantitative markers of ovarian reserve. Anti-Müllerian hormone (AMH), a gold-standard biomarker for follicular supply, and antral follicle count (AFC) are significantly lower in women with high PFAS burdens. Conversely, basal follicle-stimulating hormone (FSH) levels—a marker of diminished feedback from the ovaries—rise in tandem with PFAS exposure. This biochemical profile reinforces the hypothesis that these chemicals accelerate the depletion of the primordial follicle pool.

The Cumulative Risk: Mixture Models and BKMR Analysis

In real-world scenarios, humans are rarely exposed to a single chemical. The use of Bayesian Kernel Machine Regression (BKMR) has allowed researchers to assess the ‘cocktail effect’ of multiple PFAS. The 2025 data suggests that the combined effect of Novel PFAS is more detrimental than individual exposures. HFPO-DA, PFBA, PFBS, PFPeA, and PFPeS were identified as the primary contributors to the overall mixture effect. When these chemicals coexist in the plasma, they likely act through multiple pathways—oxidative stress, competitive binding to hormone receptors, and disruption of steroidogenesis—to compromise ovarian function.

Expert Commentary

The transition from legacy long-chain PFAS to novel shorter-chain alternatives was initially marketed as a safer pivot for human health. However, clinical data now suggests this was a ‘regrettable substitution.’ The ether-linked and shorter-chain compounds appear to be highly bioavailable and capable of disrupting delicate endocrine balances.

Mechanistically, the disruption likely occurs at the cellular level within the granulosa cells of the ovary. PFAS may induce mitochondrial dysfunction and increase reactive oxygen species (ROS), leading to accelerated follicular atresia. Furthermore, the structural similarity of some PFAS to fatty acids may allow them to interfere with lipid metabolism and steroid hormone synthesis. Clinical practitioners should be aware that environmental exposure history may be a relevant factor in patients presenting with idiopathic low ovarian reserve or POI. While we cannot yet ‘detox’ these substances from the body efficiently, identifying exposure sources—such as contaminated water or specific industrial occupations—is a critical step in patient counseling and public health advocacy.

Conclusion

The evidence connecting novel PFAS (including HFPO-DA, PFBA, PFPeA, and PFPeS) to premature ovarian insufficiency is compelling and demands immediate attention from the medical community. These substances appear to negatively impact the ovarian reserve, as evidenced by significant changes in AMH, FSH, and AFC. Future research must focus on prospective longitudinal cohorts to establish causality more firmly and animal models to elucidate the specific molecular pathways of toxicity. In the interim, health policy should aim to reduce environmental contamination, and clinicians should consider the impact of environmental disruptors when managing women’s reproductive health and fertility preservation.

References

• Qiao R, Guo F, Ding H, Sun D, Hu Q, Li Y, Zhang M, Zhang Q, Li W. Association between novel per- and poly-fluoroalkyl substances and premature ovarian insufficiency: a case-control study. Hum Reprod Open. 2025 Jul 12;2025(3):hoaf044. PMID: 40740667.
• Zhang et al. Association of Perfluoroalkyl and Polyfluoroalkyl Substances With Premature Ovarian Insufficiency in Chinese Women. J Clin Endocrinol Metab. 2018 Jul 1;103(7):2543-2551. PMID: 29986037.